Tharimmune Earlier Announced A 1-For-15 Reverse Stock Split, Will Trade On A Post-Split Basis When The Market Opens On May 28, 2024
Author: Benzinga Newsdesk | May 22, 2024 11:13am
Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that it will effect a 1-for-15 reverse stock split of its issued and outstanding shares of common stock after the close of trading on The Nasdaq Capital Market ("Nasdaq") on May 24, 2024. Tharimmune's common stock will trade on a post-split basis when the market opens on May 28, 2024 under the existing trading symbol "THAR" and the new CUSIP number 432705309. The reverse stock split was approved by Tharimmune stockholders at the Annual Meeting of Stockholders held on May 14, 2024, with the final ratio determined by the Company's Board of Directors.
Posted In: THAR